Enanta Pharmaceuticals
Market cap $253M 29.2M shares (10-K, Nov 6, 2026) × $8.69 close Nov 17, 2026
Most recent annual filing: 2025-11-15
- RESOLVE / LOTUS Ph2b readout2027RESOLVE / LOTUS Ph2b readout, 2027, notable
- EDP-978 Ph1 toplineFeb 2027EDP-978 Ph1 topline, Feb 2027, material
- STAT6 IND filing2Q 2027STAT6 IND filing, 2Q 2027, notable
- '265 Patent Pfizer opposition litigationApr 2027'265 Patent Pfizer opposition litigation, Apr 2027, routine
- MRGPRX2 IND filing4Q 2027MRGPRX2 IND filing, 4Q 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
EDP-323
EDP-235
EDP-514
EDP-978
MAVYRET
MAVIRET · glecaprevir · pibrentasvirEDP-903
EPS-5336
Capital (as filed)
- Cash
- $20.3M cash and cash equivalents · Sep 30, 2026 (10-K)
- Short-term investments
- $174M Sep 30, 2026
- Operating cash flow
- −$10.6M annual ÷ 4, year to Sep 30, 2026 (10-K)
- As stated in coverage
- $195M cash, runway fiscal 2029 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-07-02 424B5 · At-the-market program up to $75.0M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (10)
- 2026-11-17 UPDATE: Enanta (ENTA) - The Catalysts Slip Into 2027 🔒 Paid
- 2026-10-30 UPDATE: Enanta (ENTA) - The Last Lottery Ticket Comes Up Blank ★ Distilled Pro
- 2026-10-29 UPDATE: Enanta (ENTA) - The Founder-Era CEO Steps Aside 🔒 Paid
- 2026-08-11 UPDATE: Enanta (ENTA) - The ATM They Didn’t Use 🔒 Paid
- 2026-07-02 UPDATE: Enanta (ENTA) - The Shelf Wasn’t Just Housekeeping 🔒 Paid
- 2026-06-23 UPDATE: Enanta (ENTA) - The Federal Circuit Tore Up One of the Lottery Tickets 🔒 Paid
- 2026-06-18 UPDATE: Enanta (ENTA) - The FDA Said Yes. The Market Said No. 🔒 Paid
- 2026-05-12 UPDATE: Enanta (ENTA) - Q2 FY26 Sets the Clock on Zelicapavir 🔒 Paid
- 2026-02-14 UPDATE: Enanta (ENTA) - Q1 2026 Financial Update 🔒 Paid
- 2026-02-10 Enanta Pharmaceuticals (ENTA): Scientific Deep Dive for Lead and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (10 calls)
Every verdict Biotech Distilled has published on Enanta Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-10 Watch Enanta Pharmaceuticals (ENTA): Scientific Deep Dive for Lead and Pipeline Products Binary regulatory risk at the Q2 2026 FDA meeting on the RSV Phase 3 design warrants waiting before taking a position, with the cash/royalty floor providing a potential entry point on a negative outcome.
- 2026-02-14 Speculative buy speculative UPDATE: Enanta (ENTA) - Q1 2026 Financial Update Management's explicit RSV business development language de-risks the binary regulatory bet by signaling a potential partner could fund Phase 3, while smart money (Deep Track Capital) is stepping in alongside existing institutional holders.
- 2026-05-12 Speculative buy speculative UPDATE: Enanta (ENTA) - Q2 FY26 Sets the Clock on Zelicapavir The RSV partnership language survived the quarter intact alongside a hard-dated FDA path disclosure, the cash fortress is intact, and four meaningful catalysts in six months including two litigation lottery tickets maintain the asymmetric risk/reward.
- 2026-06-18 Buy core UPDATE: Enanta (ENTA) - The FDA Said Yes. The Market Said No. FDA acceptance of the HR3 subgroup Phase 3 design retires the single biggest abstract risk; the 18% drawdown into good news creates the entry the original BUY case described, with clinical risk now shifting to the more familiar 'will the effect replicate' form.
- 2026-06-23 Buy core UPDATE: Enanta (ENTA) - The Federal Circuit Tore Up One of the Lottery Tickets The U.S. patent loss was already priced in as a lottery ticket outcome, the EU acute-HCV label expansion provides a small royalty tailwind, and the core thesis of a wholly-owned antiviral in a $2.6-3.5B market backed by $227M cash remains intact.
- 2026-07-02 Watch UPDATE: Enanta (ENTA) - The Shelf Wasn't Just Housekeeping The $75M ATM activation signals no partner has materialized at acceptable terms and that Enanta is transitioning to self-funding Phase 3, introducing a 17.5% dilution overhang that dampens the asymmetry that made the stock compelling below $13.
- 2026-08-11 Speculative buy speculative UPDATE: Enanta (ENTA) - The ATM They Didn't Use Zero ATM issuance through June 30 and unchanged fiscal 2029 runway guidance confirm the shelf is defensive optionality rather than active financing, satisfying the key condition for reversing the July downgrade, though a 21% YoY royalty decline and five quarters of BD silence keep conviction at speculative rather than core.
- 2026-10-29 Speculative buy speculative UPDATE: Enanta (ENTA) - The Founder-Era CEO Steps Aside The planned CEO retirement is an orderly transition that doesn't change the science or cash runway, and the new COO's Vertex BD background may actually improve strategic optionality, but the bigger tests (ATM draw and EDP-978 data) haven't happened yet.
- 2026-10-30 Speculative buy speculative UPDATE: Enanta (ENTA) - The Last Lottery Ticket Comes Up Blank The UPC ruling invalidating the European Paxlovid patent removes the last non-dilutive upside path from litigation but doesn't change the core clinical thesis, which always rested on zelicapavir replicating and the oral biologics platform working in humans.
- 2026-11-17 Watch UPDATE: Enanta (ENTA) - The Catalysts Slip Into 2027 EDP-978 topline slipped to 1Q 2027, the STAT6 IND was delayed by a manufacturing problem, Farallon cut its stake from ~9-10% to 3.3%, and the royalty posted a second straight down quarter, leaving no catalysts scheduled for the rest of 2026 and turning this into a waiting story.
- Long call · opened Feb 17, 2026 at $13.86 · closed Jul 6, 2026 (downgraded to WATCH from long) at $14.51 · +4.7% vs XBI +29.2%
- Long call · opened Aug 12, 2026 at $13.50 · closed Nov 17, 2026 (downgraded to WATCH from long) at $8.69 · -35.6% vs XBI -8.1%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (7 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Announced the Planned Retirement of Longstanding President and Chief Executive Officer, Jay R. Luly, Ph.D. by February 2027, and the Promotion of Tara L. Kieffer, Ph.D. to Chief Operating Officer”
matched to EDP-978 · topline data
-
-
-
“We expect to report topline data from this trial in the fourth quarter of 2026.”
matched to EDP-978 · topline data -
“We are currently performing scale-up and Investigational New Drug application, or IND, enabling activities and are on track to file an IND in the second half of 2026.”
matched to EPS-3903 · regulatory submission -
“We are continuing to evaluate multiple compounds in preclinical studies and expect to select a development candidate in the second half of 2026.”
matched to MRGPRX2 Inhibitor · other · since happened Nov 16, 2026 -
“A hearing on the infringement action and counterclaim for revocation has been scheduled for September 29, 2026 and, under the UPC procedures, a decision is expected to be rendered within weeks thereafter.”
matched to Pfizer UPC (Europe) · UPC hearing and decision · since happened Oct 29, 2026 -
“We expect to initiate this study named RESOLVE in the fourth quarter of 2026, with data from the Phase 2b portion of the RESOLVE study targeted for 2027.”
matched to RESOLVE · Adult Phase 2b/3 initiation · since happened Nov 16, 2026 -
“We initiated this pediatric study named LOTUS and dosed our first participant in the third quarter of 2026, with topline data expected in 2027.”
matched to Zelicapavir · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 18, 202610-KAnnual report
- Nov 16, 2026ReleaseEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1→ BD updateEnanta's fiscal Q4 print landed after the close today with a cluster of negatives: EDP-978 Phase 1 topline slipped to 1Q 2027, the STAT6 "oral Dupixent" IND pushed to 2Q 2027 on a drug manufacturing delay, the workforce was cut by one-third, cash fell to $194.5M as RESOLVE and LOTUS ramp, and Farallon — the smart-money anchor I cited in the deep dive — quietly trimmed from ~9-10% to 3.3%.
- Nov 4, 2026ReleaseEnanta Pharmaceuticals to Participate in Upcoming Investor Conferences
- Oct 29, 20268-KCurrent report: other events→ BD updateThe UPC ruled Enanta's European Paxlovid patent (EP 4 051 265) invalid after the September 29 hearing — both Pfizer litigation lottery tickets are now torn up, and the last non-RSV, non-immunology optionality in the thesis is gone.
- Oct 28, 2026ReleaseEnanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership→ BD updateSummary on the 8-K
- Oct 28, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1→ BD updateJay Luly — the founder-era CEO who built Enanta's chemistry platform over 23 years — is retiring by February 1, 2027, right as RESOLVE heads into enrollment and EDP-978 Phase 1 nears readout; the stock dropped ~5% on the news and the successor search introduces real strategic uncertainty at the worst possible moment.
- Oct 26, 2026ReleaseEnanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
- Oct 13, 2026ReleaseEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026BD extracted 1 program update from this document → ENTA pipeline
- Sep 1, 2026ReleaseEnanta Pharmaceuticals to Participate in September Investor Conferences
- Aug 12, 202610-QQuarterly report
- Aug 10, 2026ReleaseEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
- Aug 10, 20268-KCurrent report: results of operations · EX-99.1
- Jul 2, 20268-KCurrent report: material agreement
- Jul 2, 2026424B5Prospectus supplement (offering)
- Jun 23, 2026ReleaseEnanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
- Jun 23, 20268-KCurrent report: other events
- Jun 18, 2026ReleaseEnanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
- Jun 18, 20268-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → ENTA pipeline
- May 28, 2026ReleaseEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- May 13, 202610-QQuarterly report
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 4, 2026ReleaseEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
- Mar 26, 20268-KCurrent report: other events
- Mar 12, 20268-KCurrent report: officer / director change, shareholder vote
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- Oct 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026S-8Employee plan registration
- Mar 26, 2026SCHEDULE 13G/A13G amendment